Bullous Pemphigoid

Table of Contents

  1. What is Bullous Pemphigoid?
  2. Pathogenesis: BP180 and BP230 Autoantibodies
  3. Clinical Features: Prodrome and Tense Bullae
  4. Diagnosis: Biopsy, DIF, and ELISA
  5. Differential Diagnosis: BP vs. Pemphigus Vulgaris
  6. Drug Triggers and Gliptin-Associated BP
  7. Neurological Associations
  8. Treatment: Topical Steroids, Doxycycline, and Rituximab
  9. Monitoring Disease Activity: BPDAI
  10. Prognosis and Mortality in the Elderly
  11. Research Papers
  12. Connections
  13. Featured Videos

What is Bullous Pemphigoid?

Bullous pemphigoid (BP) is the most common autoimmune blistering disorder in the Western world, characterized by autoantibodies directed against proteins within the hemidesmosome — the molecular structure anchoring the outer layer of skin (epidermis) to the deeper layer (dermis). The resultant immune assault at the basement membrane zone (BMZ) cleaves the two layers apart, producing large, firm, tense blisters that stand in stark contrast to the fragile, easily ruptured blisters of pemphigus vulgaris.

Bullous pemphigoid is overwhelmingly a disease of the elderly. The mean age at diagnosis is approximately 80 years, with incidence rising steeply with age — approximately 21–70 cases per million per year in those over 80, versus less than 1 per million in those under 45. Incidence is increasing in Western countries, partly due to population aging and partly due to the growing use of DPP-4 inhibitor (gliptin) diabetes medications that can trigger BP. In the United Kingdom, one study documented a 76% increase in BP incidence over a decade.

Despite the absence of skin detachment (unlike SJS/TEN or pemphigus in severe cases), BP in the elderly carries significant morbidity and mortality. One-year mortality in elderly BP patients approaches 20–40% — though this largely reflects comorbidities of advanced age rather than the blistering disease itself. The chronic relapsing nature, the need for prolonged immunosuppression in an already frail population, and the association with underlying neurological disease all contribute to poor outcomes.

Pathogenesis: BP180 and BP230 Autoantibodies

Bullous pemphigoid is defined immunologically by IgG autoantibodies targeting two hemidesmosomal proteins:

BP180 (BPAg2 / Collagen XVII)

BP180 is a transmembrane collagen (type XVII) with an intracellular N-terminus within the basal keratinocyte and a long extracellular ectodomain that loops through the lamina lucida of the basement membrane. The pathogenically critical domain is the NC16A domain — the extracellular region immediately adjacent to the transmembrane anchor. Anti-BP180 NC16A antibodies are found in approximately 80–90% of BP patients and their titers correlate directly with disease activity, making them the most clinically useful serologic marker for diagnosis and monitoring.

Mechanistically, anti-BP180 IgG binding activates complement (particularly C3 and C5a), recruits eosinophils and neutrophils to the DEJ, and triggers the release of proteases (elastase, MMP-9) from degranulating eosinophils that cleave the anchoring proteins of the BMZ, producing the subepidermal split. The eosinophilia in BP tissue and blood reflects this eosinophil-driven effector mechanism — a key histological feature that helps distinguish BP from other subepidermal blistering diseases.

BP230 (BPAg1)

BP230 is an intracellular plakin protein linking the hemidesmosome to the keratin intermediate filament cytoskeleton of basal keratinocytes. Anti-BP230 IgG antibodies are found in approximately 60–70% of BP patients but are less directly pathogenic than anti-BP180, as BP230 is intracellular and less accessible to circulating antibodies. Anti-BP230 antibodies may amplify disease by disrupting hemidesmosomal structural integrity indirectly.

Immunological Cascade

The full mechanism from autoantibody to blister involves:

  1. IgG anti-BP180 NC16A binding at the BMZ
  2. Complement activation (C3a, C5a anaphylatoxins released)
  3. Mast cell degranulation and eosinophil recruitment chemotaxis via IL-5, eotaxin
  4. Eosinophil degranulation → elastase, MMP-9, eosinophil cationic protein → proteolytic cleavage of BP180 extracellular domain and laminin 332
  5. Subepidermal blister formation at the lamina lucida level

Th2-skewed immunity (elevated IL-4, IL-13, IL-31) is characteristic of BP, explaining the intense pruritus (IL-31 is a potent pruritogen) and peripheral eosinophilia. The Th2 skewing provides the mechanistic rationale for dupilumab (IL-4Rα blockade) and omalizumab (anti-IgE) as emerging BP therapies.

Clinical Features: Prodrome and Tense Bullae

Prodromal Phase (Weeks to Months)

A distinctive and often diagnostically confusing feature of BP is the prolonged prodromal phase — lasting weeks to months — during which patients experience intense pruritus and urticarial (hive-like) or eczematous skin changes without blisters. This "pre-bullous" BP is commonly misdiagnosed as chronic urticaria, eczema, contact dermatitis, or scabies. Approximately 50% of BP patients never develop classic bullae, presenting only with persistent pruritic urticarial plaques — "non-bullous BP" or "urticarial phase BP." This makes diagnosis particularly challenging.

Classic Bullous Phase

When bullae develop, they are characteristically tense — thick-walled, firm, difficult to rupture with finger pressure — arising on an urticarial or erythematous base. The tenseness reflects the subepidermal location of the blister: the entire epidermis forms the blister roof, which is far more robust than the thin epidermal fragments that form the fragile roof of intraepidermal pemphigus blisters. Bullae are typically large (0.5–3 cm), filled with clear or blood-tinged fluid, and heal over days without scarring when they rupture (though milia may form at healing sites).

Distribution

BP preferentially involves the flexural surfaces and trunk:

The face, palms, soles, and scalp are less commonly involved (unlike pemphigus, where the scalp is frequently affected). Symmetric distribution is typical.

Mucous Membrane Involvement

In contrast to pemphigus vulgaris (where mucous membrane involvement is nearly universal and often the presenting feature), mucous membrane erosions occur in only approximately 20% of BP patients and are typically mild when present. Oral erosions are less painful and less disabling than in pemphigus. The relative sparing of mucous membranes in BP is explained by the predominance of BP180 at the cutaneous BMZ, with less expression in oral mucosal tissue.

Diagnosis: Biopsy, DIF, and ELISA

Skin Biopsy — Histology

Biopsy of an intact fresh bulla shows a subepidermal blister with a preserved, non-necrotic epidermal roof (contrast with SJS/TEN where the epidermis is necrotic). The blister cavity and the upper dermis contain abundant eosinophils — a key distinguishing feature of BP that helps differentiate it from other subepidermal blistering diseases (epidermolysis bullosa acquisita, dermatitis herpetiformis, linear IgA disease). Eosinophilic spongiosis in the epidermis adjacent to the blister is an additional supportive finding.

Direct Immunofluorescence (DIF) — Gold Standard

Perilesional skin biopsy stained with fluorescent anti-human antibodies reveals the pathognomonic linear IgG and/or C3 deposition along the basement membrane zone. The linear band follows the DEJ continuously without the intercellular "fishnet" IgG pattern seen in pemphigus. DIF sensitivity for BP is approximately 90%. IgG is present in 80–90% of cases; C3 is present in up to 95% and may be the sole positive finding in early disease.

Indirect immunofluorescence (IIF) on salt-split skin places the IgG fluorescence on the epidermal (roof) side of the artificial blister — indicating that the antigen is located in the lamina lucida/upper BMZ, typical of BP. In contrast, epidermolysis bullosa acquisita (targeting type VII collagen in the sub-lamina densa) shows dermal-side IgG on salt-split skin.

ELISA — BP180 NC16A and BP230

Commercially available ELISA assays for anti-BP180 NC16A and anti-BP230 IgG provide quantitative titers that:

BP can be diagnosed with confidence when clinical features, subepidermal histology with eosinophils, linear DIF at the BMZ, and positive anti-BP180 ELISA are all present.

BPDAI for Disease Quantification

The Bullous Pemphigoid Disease Area Index (BPDAI) was developed and validated as a standardized scoring tool to quantify disease extent for clinical trials and treatment monitoring. It scores blisters/erosions and urticarial/eczematous lesions separately, on skin and mucous membranes.

Differential Diagnosis: BP vs. Pemphigus Vulgaris

The most important clinical differential for BP is pemphigus vulgaris (PV). The distinction is clinically significant because the treatments, prognosis, and specific immunological mechanisms differ substantially:

Drug Triggers and Gliptin-Associated BP

Drug-induced BP is increasingly recognized, with the DPP-4 inhibitors (gliptins) — widely used for type 2 diabetes — emerging as the most significant drug class.

DPP-4 Inhibitors (Gliptins)

Sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin have all been associated with BP. Gliptin-induced BP has distinctive features that differentiate it from idiopathic BP:

The proposed mechanism: DPP-4 (CD26) is expressed on T regulatory cells and may alter immune tolerance at the DEJ; DPP-4 inhibition may disrupt this tolerance, unmasking autoreactive T-cell responses to BP antigens.

Other Implicated Drugs

Neurological Associations

A striking and now well-established feature of BP is its association with neurological diseases. Approximately 25–35% of BP patients have a concurrent neurological condition, predominantly:

This association is not explained by age alone (elderly patients have higher rates of neurological disease, but the BP–neurological association persists after age-matching). The leading hypothesis is a cross-reactive autoimmune mechanism: the BP180 and BP230 proteins have neuronal isoforms expressed in the brain (neuronal BP180 and dystonin/BPAG1-n). In patients with neurological disease, damage to the blood-brain barrier may expose these neuronal autoantigens, generating autoantibodies that cross-react with the skin isoforms of the same proteins, triggering BP as a secondary bystander phenomenon.

The clinical implication: in an elderly patient presenting with new BP, a search for underlying neurological conditions is warranted. Conversely, patients with dementia or Parkinson's disease who develop unexplained pruritic skin lesions should be evaluated for BP.

Treatment: Topical Steroids, Doxycycline, and Rituximab

First-Line: High-Potency Topical Corticosteroids

For localized or moderate BP, high-potency topical corticosteroids (e.g., clobetasol propionate 0.05% cream) are the preferred first-line treatment — particularly in the elderly, where systemic corticosteroids carry significant toxicity. The landmark Dreno 2002 RCT demonstrated that clobetasol propionate applied to the entire body surface achieved superior disease control with fewer serious adverse events (diabetes, infection, sepsis, death) compared to systemic prednisone. This was a paradigm shift from reflexive systemic steroid use.

For extensive BP (large BSA involvement), topical-alone may be impractical; oral corticosteroids (prednisone 0.5 mg/kg/day) are used with the goal of rapid tapering. The key principle in the elderly: minimize systemic corticosteroid exposure.

Doxycycline Plus Niacinamide

The combination of doxycycline (100 mg twice daily) plus niacinamide (500 mg three times daily) has anti-inflammatory activity via MMP inhibition and anti-eosinophilic mechanisms. Multiple trials, including a UK multi-center RCT comparing doxycycline to prednisolone, demonstrated non-inferiority of doxycycline for initial disease control with a significantly better safety profile (fewer serious adverse events) in elderly BP patients. Doxycycline is now a preferred systemic option — particularly for frail elderly patients where steroid side effects are the primary concern.

Steroid-Sparing Adjuvants

Rituximab for Refractory BP

Rituximab (anti-CD20 B-cell depletion) has shown efficacy in refractory or corticosteroid-dependent BP uncontrolled with conventional agents. Given the pathogenic role of IgG autoantibodies, the mechanistic rationale mirrors its use in pemphigus vulgaris. Dosing protocols (1000 mg IV on days 1 and 15, or 375 mg/m² ×4 doses) have produced sustained remissions in case series and small cohort studies. A randomized controlled trial (RIGOUR) is evaluating rituximab vs. standard care in BP.

Emerging Biologics

Monitoring Disease Activity: BPDAI

Monitoring BP during treatment requires both clinical and serological tools:

Prognosis and Mortality in the Elderly

BP in the elderly is associated with substantial mortality, though the blistering disease itself is not usually the proximate cause of death:

Research Papers

Key peer-reviewed studies on bullous pemphigoid pathogenesis, diagnosis, and treatment. Each PMID link opens the study on PubMed.

  1. Diaz LA, et al. Bullous pemphigoid antigen is the 230-kD human hemidesmosomal protein. J Clin Invest. 1990;86(4):1088-1094. PMID 2402454
  2. Giudice GJ, et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151(10):5742-5750. PMID 8228262
  3. Joly P, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. PMID 11821508
  4. Murrell DF, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479-485. PMID 21839523
  5. Amber KT, et al. Gliptin use and the risk of bullous pemphigoid: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(7):1253-1259. PMID 28371142
  6. Langan SM, et al. Bullous pemphigoid and pemphigus vulgaris -- incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180. PMID 18614511
  7. Joly P, et al. A randomized study of the combination of two immunosuppressant drugs in combination with high-potency topical steroids. J Invest Dermatol. 2012;132(1):113-120. PMID 21900952
  8. Chen J, Li L, Chen J. Dupilumab for bullous pemphigoid: a systematic review and meta-analysis. J Dermatol Treat. 2022;33(4):1985-1991. PMID 33779424
  9. Stinco G, et al. Neurological disorders in patients with bullous pemphigoid. Eur J Dermatol. 2014;24(5):587-591. PMID 25264070
  10. Meijer JM, et al. Rituximab treatment in bullous pemphigoid: a systematic review. Acta Derm Venereol. 2021;101(1):adv00395. PMID 33399215
  11. Williams HC, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630-1638. PMID 28302366
  12. Schmidt E, et al. Bullous pemphigoid. Lancet. 2019;394(10197):451-462. PMID 31268280

Curated PubMed topic searches:

  1. PubMed: BP180 pathogenesis
  2. PubMed: Gliptin-associated BP
  3. PubMed: DIF diagnosis BP
  4. PubMed: Topical steroids BP
  5. PubMed: BP neurological
  6. PubMed: Rituximab in BP
  7. PubMed: BP elderly mortality
  8. PubMed: Dupilumab in BP

Back to Table of Contents

Connections

Back to Table of Contents